Fig. 2.

Antibody response against SARS-CoV-2 across the clinical spectrum of COVID-19 in the course of acute and convalescent phases of infection. (a-e) Children in the acute or convalescent phases of SARS-CoV-2 infection were grouped based on their diagnosis at hospital admission as asymptomatic, mild, moderate or severe. (a) Donuts graphs show the frequency of children that produced IgG and/or IgM antibodies to the Spike/RBD protein of SARS-CoV-2 in the course of acute infection. Pearson's Chi square test, p<0.05 (IgG+IgM+, asymptomatic vs mild; IgG-IgM-, asymptomatic vs severe). (b) Plasma levels of IgG and IgM antibodies directed to the Spike/RBD protein were measured in SARS-CoV-2-seropositive children during acute phase (n=31 and n=38, n=82 and n=115, n=26 and n=38 for IgG and IgM levels in asymptomatic, mild and moderates, respectively). (c) Donuts graphs show the frequency of children that produced IgG and/or IgM antibodies to the Spike/RBD protein of SARS-CoV-2 in the convalescent phase of the infection (IgG-IgM-, mild vs severe, p<0.05). (d) Plasma levels of IgG and IgM antibodies directed to the Spike/RBD protein were measured in SARS-CoV-2-seropositive children during the convalescent phase of the infection (n=7 and n=6, n=59 and n=47, n=19 and n=14, n=2 y n=3 for IgG and IgM levels in asymptomatic, mild, moderates and severe, respectively). (e) Neutralization antibody titers in the course of acute (asymptomatic, n=4; mild, n=21; and moderate, n=9) and convalescent phases (asymptomatic, n=5; mild, n=26; moderate, n=11 and severe, n=2) of the infection. Dotted line indicates the cut-off value in b and d. Median and min to max of n donors are shown in b, d, and e. P values were determined by Pearson's Chi square test or Fisher's exact test, Kruskal-Wallis test and Mann-Whitney U test: * p<0.05, ** p<0.01. Acute (white circle), Convalescent (light grey circle), MIS-C (dark grey circle). Asymptomatic (lilac circle), mild (pink circle), moderate (violet circle), severe (purple circle).